
RENASYS* GO tNPWT brings ambulatory and post-acute patients powerful, portable negative pressure wound therapy that supports the management of complex wounds.
• Intuitive interface that's easy to use for providers and patients
• Intuitive safety alerts, including low pressure, high vacuum, blockage, canister full, and low battery
• Home health mode that locks buttons to protect provider therapy settings
• Disposable canisters and easy cleaning for sanitary operation
• Compatibility with RENASYS* TOUCH tNPWT for seamless transition from acute to post-acute care
• Suitable for a wide variety of wound types and care settings – easing the transition from acute to outpatient, home care, and long-term care
• A range of digital pressure settings for personalized therapy
• Continuous and intermittent modes that provides a soft, cushioned channel for patient comfort during therapy
• Compact and light weight – only 2.4lb – for greater patient mobility
• Sleek design and quiet operation
• 20-hour battery life – charges and operates while plugged in
• Black case with optional strap settings for customized carrying
Exclusive distribution through Rotech Healthcare enables:
• Easy intake process
• Continuity of care
• Experienced, dedicated wound care team
• Smooth transition from an inpatient facility to a home care setting
• 90-minute approval process
• 7-day-a-week, same-day discharge
• 24/7 clinical and technical support
• Insurance specialists and in-network with many insurances
RENASYS* GO is indicated for patients who would benefit from a suction device (negative pressure wound therapy), as it may promote wound healing via removal of fluids, including irrigation and body fluids, wound exudates, and infectious materials.
Appropriate wound types include:
• Chronic
• Acute
• Traumatic
• Sub-Acute and dehisced wounds
• Ulcers (such as pressure or diabetic)
• Partial-thickness burns
• Flaps and grafts
Use of RENASYS* GO is contraindicated in the presence of:
• Untreated osteomyelitis
• Exposed arteries, veins, organs, or nerves
• Necrotic tissue with eschar present
• Malignancy in wound (with exception of palliative care to enhance quality of life)
• Non-enteric and unexplored fistulas
• Anastomotic sites
1. Carefully monitor patients for signs of bleeding, which may lead to interruption in therapy and hemodynamic instability. If such symptoms are observed, immediately discontinue therapy, take appropriate measures to control bleeding, and contact treating clinician.
2. Patients suffering from difficult hemostasis or who are receiving anticoagulant therapy have an increased risk of bleeding. During therapy, avoid using hemostatic products that, if disrupted, may increase the risk of bleeding.
3. Do not use directly on exposed blood vessels or organs. Sharp edges such as bone fragments must be covered or removed prior to initiating therapy, due to risk of puncturing organs or blood vessels drawn closer under the action of negative pressure.
4. NPWT has not been studied on pediatric patients. Patient size and weight should be considered when prescribing the device.
5. Foam or gauze must not be tightly packed or forced into any wound area. Over-packing may interfere with distribution of NPWT evenly across the wound. This may decrease the ability of the wound to properly contract and permit exudate to remain in wound.
6. In the event defibrillation is required, disconnect device from wound dressing prior to defibrillation. Remove wound dressing only if its location will interfere with defibrillation.
7. Device is not MRI compatible. Do not bring device into MRI suite. Prior to entering MRI suite, disconnect device from dressing. Dressing can remain intact on patient.
8. Do not use the device in oxygen enriched environment or in areas where there is danger of explosion (eg, hyperbaric oxygen unit).
9. When operating, transporting, or disposing of device and accessories, there is risk of infectious liquids being aspirated or contamination of device assembly through incorrect use. Universal precautions should be observed whenever working with potentially contaminated components or equipment.
10. Device and canister kits are provided non-sterile and should not be placed within a sterile field.
Prior to storage for more than 2 months, ensure that the battery is fully charged. Some battery discharge may occur in storage. During long-term storage, recharge the battery every ten months. RENASYS* GO should be stored between 0°C-25°C
(32°F-77°F) for optimal battery performance, but can be stored between -10°C-55°C (14°F-31°F) for short periods of time.
Accommodates large wounds | ● |
Accommodates small wounds | ● |
Adjustable PSI | ● |
Antimicrobial interface available | ● |
Battery-operated | ● |
Disposable | |
Foam interface | ● |
Gauze interface | ● |
Instillation function | |
Intermittent-pressure setting | ● |
Irrigation function | |
Portable (under 1lb) | |
Single-use – 7 days | |
Single-use – 10 days | |
Single-use – 15 days | |
Single-use – 30 days | |
Touchscreen | |
Usable on closed wounds | |
Usable on open wounds | ● |
Variable pressure setting | ● |
Educational Material Available | ● |
Free Samples/Trials Available | ● |
Published Clinical Article Available | ● |
Acute Wounds
Burns
Chronic Wounds
Dehisced Wounds
Diabetic Foot
Flaps and Grafts
Pressure Ulcers
Traumatic Wounds
For complete application information, please see the RENASYS* GO Clinical User Manual.
For complete removal and change frequency information, please see the RENASYS* GO Clinical User Manual.
Both foam and gauze dressing kits are available for the RENASYS* GO, plus pump and dressing accessories.
For complete construction information, please see the RENASYS* GO Clinical User Manual.
Please contact Smith+Nephew for complete warranty information.
For clinical testing information, please contact Smith+Nephew.
For complete technical specifications, please see the RENASYS* GO Clinical User Manual.
For over 150 years, Smith+Nephew has taken a pioneering approach to product design and services, helping to reduce the human and economic costs of wounds.
*Trademark of Smith+Nephew